Copyright
©The Author(s) 2024.
World J Gastroenterol. Aug 21, 2024; 30(31): 3654-3667
Published online Aug 21, 2024. doi: 10.3748/wjg.v30.i31.3654
Published online Aug 21, 2024. doi: 10.3748/wjg.v30.i31.3654
Table 2 Clinical studies involving B7 homolog 3-targeting agents in pancreatic cancer
Ref. | Agent/drug | Route of administration | Study participants | Status |
NCT05293496, phase I[106] | Vobramitamab duocarmazine1 in combination with lorigerlimab2 | Intravenous | Patients with relapsed or refractory, unresectable, locally advanced, or metastatic solid tumors including PC | Recruiting |
NCT06330064, phase II[110] | I-DXD3 | Intravenous | Patients with recurrent or metastatic solid tumors, including PDAC | Recruiting |
NCT02628535, phase I[113] | Orlotamab4 | Intravenous | Patients with unresectable or metastatic B7-H3-expressing neoplasms including PC | Terminated |
NCT05143151, phase I/phase II[117] | CD276 CAR T cells | Intravenous | Adult patients with refractory PC | Recruiting |
NCT06158139, phase I[118] | Ic9-CAR.B7-H3 T cells | Intravenous | Adult patients with refractory PDAC | Not yet recruiting |
- Citation: Perovic D, Dusanovic Pjevic M, Perovic V, Grk M, Rasic M, Milickovic M, Mijovic T, Rasic P. B7 homolog 3 in pancreatic cancer. World J Gastroenterol 2024; 30(31): 3654-3667
- URL: https://www.wjgnet.com/1007-9327/full/v30/i31/3654.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i31.3654